Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01701323 · ClinicalTrials.gov registry record · Phase 1
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Nohla Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01701323 is a Phase 1 study that was terminated before completion, run by Nohla Therapeutics. The registered enrollment target is 7 participants.
The verdict
NCT01701323, a Phase 1 study, was terminated before completion, sponsored by Nohla Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This pilot clinical trial studies infusion of expanded cord blood hematopoietic progenitor cells following combination chemotherapy in treating younger patients with acute myeloid leukemia that has relapsed or has not responded to treatment. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy also kills healthy infection-fighting cells, increasing the risk of infection. The infusion of expanded cord blood hematopoietic progenitor cells may be able to replace blood-forming cells that were destroyed by chemotherapy. This cellular therapy may decrease the risk of infection following chemotherapy.
Interventions
- DRUG Cytarabine
- DRUG Fludarabine Phosphate
- DRUG Filgrastim
- BIOLOGICAL Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-12-10 |
| Est. Completion | 2018-05-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01701323
The ClinicalTrials.gov registry entry for NCT01701323 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nohla Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cytarabine is the first listed.
NCT01701323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01701323 about?
NCT01701323 is a clinical study titled "Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia". This pilot clinical trial studies infusion of expanded cord blood hematopoietic progenitor cells following combination chemotherapy in treating younger patients with acute myeloid leukemia that has relapsed or has not responded to treatment. Chemotherapy drugs work in different ways to stop the grow...
What is the current status of trial NCT01701323?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2012-12-10. Estimated completion is 2018-05-10.
What interventions are being tested in trial NCT01701323?
The interventions under investigation include: Cytarabine (DRUG), Fludarabine Phosphate (DRUG), Filgrastim (DRUG), Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT01701323?
This trial is sponsored by Nohla Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.